Xeris Biopharma Holdings, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Xeris amended its non-employee director compensation policy effective July 1, 2026. Policy establishes: annual board retainer of $50,000; committee chair retainers of $10,000–$20,000; initial equity awards of ~$450,000 per new director (50% RSUs, 50% options, 3-year vest); annual equity awards of ~$300,000 per continuing director (50/50 RSUs/options, 1-year vest); and full acceleration of director equity upon a Sale Event. The policy has been amended multiple times since adoption in April 2018.
Why this rating
Standard governance policy amendment. Director compensation is fixed overhead (~$750k–$1.2M annually for typical 5–7 person board) — routine relative to $731M market cap, <0.2% of company size.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.